Skip to main content
fghjkjhb

Evidence gap analysis

Strategic analysis of the sufficiency of evidence to obtain reimbursement and HTA approval in Europe and recommendations about evidence generation

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Two projects awarded under the 2024 "Subsidy scheme for promising care" in the Netherlands

In April 2024, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced two projects that were awarded under round 9 of the subsidy scheme for promising care in 2024:

  • Targeted muscle reinnervation during leg amputation in patients with peripheral artery disease;
  • Thrombectomy by catheterization in adult patients with a high-risk pulmonary embolism.

The project for targeted muscle reinnervation during leg amputation in patients with peripheral artery disease (Prevent PAP trial) will start in June 2024 and will last for four years and five months. After the completion of the project, the research results will be submitted to the ZIN around November 2028 for the decision about inclusion in Basic Health Insurance. The publication of the ZIN position on reimbursement under the Basic Insurance Package is scheduled for May 2029.

The project for thrombectomy by catheterization in adult patients with a high-risk pulmonary embolism (TORPEDO-NL) started on April 01, 2024, and will last for four years and five months. After the completion of the project, the research results will be submitted to ZIN around September 2028 for the decision about inclusion in Basic Health Insurance. The publication of the ZIN position on reimbursement under the Basic Insurance Package is scheduled for March 2029.

See more information in Dutch here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.